XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

Publikation

XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.

Wissenschaftlicher Artikel/Review - 29.10.2024

Woelfel Simon, Dütschler Joel, Junker Daniel, König Marius, Graf Nicole, Krieger-Grübel Claudia, Truniger Samuel, Oikonomou Vasileios, Leinenkugel Georg, Koller Seraina, Metzger-Peter Katline, Wyss Jacqueline, Krupka Niklas, Frei Nicola Fabian, STAR SIGN Study Investigators, Albrich Werner, Friedrich Matthias, Niess Jan-Hendrik, Schneiderhan-Marra Nicole, Dulovic Alex, Misselwitz Benjamin, Korte Wolfgang C, Bürgi Justus J, Brand Stephan

Zitation

Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger-Grübel C, Truniger S, Oikonomou V, Leinenkugel G, Koller S, Metzger-Peter K, Wyss J, Krupka N, Frei N, STAR SIGN Study Investigators, Albrich W, Friedrich M, Niess J, Schneiderhan-Marra N, Dulovic A, Misselwitz B, Korte W, Bürgi J, Brand S. XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease. Aliment Pharmacol Ther 2024

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Aliment Pharmacol Ther 2024

Veröffentlichungsdatum

29.10.2024

eISSN (Online)

1365-2036

Kurzbeschreibung/Zielsetzung

Variant-adapted COVID-19 vaccines are recommended for patients with inflammatory bowel disease (IBD). However, many patients rely on pre-existing immunity by original vaccines or prior infections.